tetano
Editor, Senior Moderator
Arch Iran Med
. 2022 Jan 1;25(1):17-25.
doi: 10.34172/aim.2022.04.
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications
Ali Reza Sima[SUP] 1 [/SUP], Bahar Saberzadeh-Ardestani[SUP] 1 [/SUP], Homayoon Vahedi[SUP] 1 [/SUP], Hafez Fakheri[SUP] 2 [/SUP], Fariborz Mansour-Ghanaei[SUP] 3 [/SUP], Iradj Maleki[SUP] 2 [/SUP], Siavosh Nasseri-Moghaddam[SUP] 1 [/SUP], Hasan Vosoghinia[SUP] 4 [/SUP], Mohammad Reza Ghadir[SUP] 5 [/SUP], Ahmad Hormati[SUP] 5 6 [/SUP], Amir Kasaeian[SUP] 1 7 [/SUP], Amir Reza Radmard[SUP] 8 [/SUP], Bardia Khosravi[SUP] 1 [/SUP], Masoud Malekzadeh[SUP] 1 [/SUP], Sudabeh Alatab[SUP] 1 [/SUP], Anahita Sadeghi[SUP] 1 [/SUP], Nayyereh Aminisani[SUP] 9 [/SUP], Hossein Poustchi[SUP] 1 [/SUP], Elnaz Gonoudi[SUP] 1 [/SUP], Amir Anushiravani[SUP] 1 [/SUP], Maryam Rayatpisheh[SUP] 1 [/SUP], Jean-Frederic Colombel[SUP] 10 [/SUP], Ryan C Ungaro[SUP] 10 [/SUP], Reza Malekzadeh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Most data on the effect of inflammatory bowel disease (IBD) and its treatments on coronavirus disease 2019 (COVID-19) outcomes have not had non-IBD comparators. Hence, we aimed to describe COVID-19 outcomes in IBD compared to non-IBD patients.
Methods: We conducted a prospective cohort study of registered IBD patients with confirmed COVID-19 from six provinces in Iran from February to April 2020. Proven COVID-19 patients were followed up at four weeks and the frequency of outcomes was assessed. Multivariable logistic regression was used to assess associations between demographics, clinical characteristics and COVID-19 outcomes.
Results: Overall, 2159 IBD patients and 4721 household members were enrolled, with 84 (3.9%) and 49 (1.1%) participants having confirmed COVID-19, respectively. Household spread of COVID-19 was not common in this cohort (1.2%). While hospitalization was significantly more frequent in IBD patients compared with non-IBD household members (27.1% vs. 6.0%, P=0.002), there was no significant difference in the frequency of severe cases. Age and presence of IBD were positively associated with hospitalization in IBD compared with non-IBD household members (OR: 1.06, 95% CI: 1.03-1.10; OR: 5.7, 95% CI: 2.02- 16.07, respectively). Age, presence of new gastrointestinal symptoms, and 5-aminosalicylic acid (5-ASA) use were associated with higher hospitalization rate in IBD patients (OR: 1.13, 95% CI: 1.05-1.23; OR: 6.49, 95% CI: 1.87-22.54; OR: 6.22, 95% CI: 1.90-20.36, respectively). Anti-tumor necrosis factor (TNF) was not associated with more severe outcomes.
Conclusion: Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association.
Keywords: COVID-19; IBD medication; Inflammatory bowel disease.
. 2022 Jan 1;25(1):17-25.
doi: 10.34172/aim.2022.04.
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications
Ali Reza Sima[SUP] 1 [/SUP], Bahar Saberzadeh-Ardestani[SUP] 1 [/SUP], Homayoon Vahedi[SUP] 1 [/SUP], Hafez Fakheri[SUP] 2 [/SUP], Fariborz Mansour-Ghanaei[SUP] 3 [/SUP], Iradj Maleki[SUP] 2 [/SUP], Siavosh Nasseri-Moghaddam[SUP] 1 [/SUP], Hasan Vosoghinia[SUP] 4 [/SUP], Mohammad Reza Ghadir[SUP] 5 [/SUP], Ahmad Hormati[SUP] 5 6 [/SUP], Amir Kasaeian[SUP] 1 7 [/SUP], Amir Reza Radmard[SUP] 8 [/SUP], Bardia Khosravi[SUP] 1 [/SUP], Masoud Malekzadeh[SUP] 1 [/SUP], Sudabeh Alatab[SUP] 1 [/SUP], Anahita Sadeghi[SUP] 1 [/SUP], Nayyereh Aminisani[SUP] 9 [/SUP], Hossein Poustchi[SUP] 1 [/SUP], Elnaz Gonoudi[SUP] 1 [/SUP], Amir Anushiravani[SUP] 1 [/SUP], Maryam Rayatpisheh[SUP] 1 [/SUP], Jean-Frederic Colombel[SUP] 10 [/SUP], Ryan C Ungaro[SUP] 10 [/SUP], Reza Malekzadeh[SUP] 1 [/SUP]
Affiliations
- PMID: 35128908
- DOI: 10.34172/aim.2022.04
Abstract
Background: Most data on the effect of inflammatory bowel disease (IBD) and its treatments on coronavirus disease 2019 (COVID-19) outcomes have not had non-IBD comparators. Hence, we aimed to describe COVID-19 outcomes in IBD compared to non-IBD patients.
Methods: We conducted a prospective cohort study of registered IBD patients with confirmed COVID-19 from six provinces in Iran from February to April 2020. Proven COVID-19 patients were followed up at four weeks and the frequency of outcomes was assessed. Multivariable logistic regression was used to assess associations between demographics, clinical characteristics and COVID-19 outcomes.
Results: Overall, 2159 IBD patients and 4721 household members were enrolled, with 84 (3.9%) and 49 (1.1%) participants having confirmed COVID-19, respectively. Household spread of COVID-19 was not common in this cohort (1.2%). While hospitalization was significantly more frequent in IBD patients compared with non-IBD household members (27.1% vs. 6.0%, P=0.002), there was no significant difference in the frequency of severe cases. Age and presence of IBD were positively associated with hospitalization in IBD compared with non-IBD household members (OR: 1.06, 95% CI: 1.03-1.10; OR: 5.7, 95% CI: 2.02- 16.07, respectively). Age, presence of new gastrointestinal symptoms, and 5-aminosalicylic acid (5-ASA) use were associated with higher hospitalization rate in IBD patients (OR: 1.13, 95% CI: 1.05-1.23; OR: 6.49, 95% CI: 1.87-22.54; OR: 6.22, 95% CI: 1.90-20.36, respectively). Anti-tumor necrosis factor (TNF) was not associated with more severe outcomes.
Conclusion: Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association.
Keywords: COVID-19; IBD medication; Inflammatory bowel disease.